JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Authors
Keywords
-
Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 16, Issue 12, Pages 843-862
Publisher
Springer Nature
Online
2017-11-06
DOI
10.1038/nrd.2017.201
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- Janus kinase inhibition for immunosuppression in solid organ transplantation: Is there a role in complex immunologic challenges?
- (2017) Cody A. Moore et al. HUMAN IMMUNOLOGY
- Impact of tofacitinib treatment on human B-cells in vitro and in vivo
- (2017) Marta Rizzi et al. JOURNAL OF AUTOIMMUNITY
- Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib
- (2017) Brett King et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- (2017) Lucy Y. Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tofacitinib for the treatment of alopecia areata and variants in adolescents
- (2017) Brittany G. Craiglow et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- (2017) Peter C. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Malignancy and Janus Kinase Inhibition
- (2017) Padmapriya Sivaraman et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- A case of refractory dermatomyositis responsive to tofacitinib
- (2017) Julie J. Paik et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
- (2017) Josef S. Smolen et al. Arthritis & Rheumatology
- Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate
- (2017) A. J. Kivitz et al. Arthritis & Rheumatology
- Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis
- (2017) Mark C. Genovese et al. Arthritis & Rheumatology
- Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
- (2017) Roy Fleischmann et al. Arthritis & Rheumatology
- Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition
- (2016) Jean-Baptiste Telliez et al. ACS Chemical Biology
- Reversal of Alopecia Universalis by Tofacitinib: A Case Report
- (2016) Morton Scheinberg et al. ANNALS OF INTERNAL MEDICINE
- Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques
- (2016) Philip G Conaghan et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib for polyarteritis nodosa: a tailored therapy
- (2016) Doron Rimar et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings
- (2016) Mark C Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
- (2016) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study
- (2016) V.J. Ludbrook et al. BRITISH JOURNAL OF DERMATOLOGY
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
- (2016) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation
- (2016) Tomohiro Koga et al. CLINICAL IMMUNOLOGY
- Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis
- (2016) Roland Martin et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis
- (2016) Li Li et al. EUROPEAN RESPIRATORY JOURNAL
- Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1
- (2016) Jason G. Kettle et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2
- (2016) Jason G. Kettle et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Phosphoproteomic Analyses of Interleukin 2 Signaling Reveal Integrated JAK Kinase-Dependent and -Independent Networks in CD8 + T Cells
- (2016) Sarah H. Ross et al. IMMUNITY
- Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
- (2016) Roy Fleischmann et al. International Journal of Rheumatic Diseases
- Tofacitinib Response in Juvenile Idiopathic Arthritis (JIA) and Collagenous Colitis
- (2016) Bryon Tseng et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study
- (2016) James Krueger et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food
- (2016) Manisha Lamba et al. JOURNAL OF CLINICAL PHARMACOLOGY
- JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation
- (2016) Wataru Amano et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis
- (2016) Jashin J. Wu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy of tofacitinib in treatment of alopecia universalis in two patients
- (2016) A.K. Gupta et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
- (2016) Sally Wenzel et al. LANCET
- Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus
- (2016) L Kahl et al. LUPUS
- Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling
- (2016) Geoffrey A Smith et al. Nature Chemical Biology
- Baricitinib in Patients with Refractory Rheumatoid Arthritis
- (2016) Mark C. Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Network pharmacology of JAK inhibitors
- (2016) Devapregasan Moodley et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor
- (2016) Christina Charles-Schoeman et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist
- (2016) Christina Charles-Schoeman et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Long-term activation of the innate immune system in atherosclerosis
- (2016) Anette Christ et al. SEMINARS IN IMMUNOLOGY
- Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells
- (2016) Robert E. Chapin et al. TOXICOLOGICAL SCIENCES
- Relationship Between Baseline and Early Changes in C-Reactive Protein and Interleukin-6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis
- (2016) Jianmei Wang et al. ARTHRITIS CARE & RESEARCH
- Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease
- (2016) Malgorzata Szelag et al. Oncotarget
- Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis
- (2016) Drew J. B. Kurtzman et al. JAMA Dermatology
- Topical Ruxolitinib for the Treatment of Alopecia Universalis
- (2016) Brittany G. Craiglow et al. JAMA Dermatology
- The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis
- (2016) Philip J. Mease et al. Arthritis & Rheumatology
- Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- (2016) Mark C. Genovese et al. Arthritis & Rheumatology
- A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy
- (2016) Joel M. Kremer et al. Arthritis & Rheumatology
- Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments
- (2016) Fenglong Xie et al. Arthritis & Rheumatology
- Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction
- (2016) Yasuko Furumoto et al. Arthritis & Rheumatology
- Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
- (2016) Nicola A Hanania et al. Lancet Respiratory Medicine
- Molecular mechanisms of pruritus
- (2016) J. Meng et al. Current Research in Translational Medicine
- Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients
- (2015) F. Vincenti et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
- (2015) Christina Charles-Schoeman et al. ANNALS OF THE RHEUMATIC DISEASES
- The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
- (2015) Kevin L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors
- (2015) W Gao et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
- (2015) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-22: Immunobiology and Pathology
- (2015) Jarrod A. Dudakov et al. Annual Review of Immunology
- The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
- (2015) John J. O'Shea et al. Annual Review of Medicine
- A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis
- (2015) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
- (2015) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor
- (2015) N. Punwani et al. BRITISH JOURNAL OF DERMATOLOGY
- The role of lymphocytes in the development and treatment of alopecia areata
- (2015) Hongwei Guo et al. Expert Review of Clinical Immunology
- Tofacitinib for the treatment of moderate-to-severe psoriasis
- (2015) Andrea Chiricozzi et al. Expert Review of Clinical Immunology
- The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling
- (2015) Wataru Amano et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases
- (2015) Luc J. Farmer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Super-enhancers delineate disease-associated regulatory nodes in T cells
- (2015) Golnaz Vahedi et al. NATURE
- Type I/II cytokines, JAKs and new strategies for treating autoimmune diseases
- (2015) Daniella M. Schwartz et al. Nature Reviews Rheumatology
- Preliminary response to Janus kinase inhibition with baricitinib in chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE)
- (2015) G Montealegre et al. Pediatric Rheumatology
- Cardiovascular risk factor management in patients with RA compared to matched non-RA patients
- (2015) Evo Alemao et al. RHEUMATOLOGY
- Tofacitinib With Methotrexate in Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial
- (2015) Vibeke Strand et al. ARTHRITIS CARE & RESEARCH
- Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
- (2015) Vibeke Strand et al. ARTHRITIS RESEARCH & THERAPY
- Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
- (2015) Vibeke Strand et al. ARTHRITIS RESEARCH & THERAPY
- Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial
- (2015) Joel M Kremer et al. ARTHRITIS RESEARCH & THERAPY
- Tofacitinib Citrate for the Treatment of Vitiligo
- (2015) Brittany G. Craiglow et al. JAMA Dermatology
- Disease Activity in Rheumatoid Arthritis and the Risk of Cardiovascular Events
- (2015) D. H. Solomon et al. Arthritis & Rheumatology
- A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
- (2015) Roy M. Fleischmann et al. Arthritis & Rheumatology
- VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib
- (2015) Christina Charles-Schoeman et al. Arthritis & Rheumatology
- An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy
- (2015) Vijay U. Rao et al. Arthritis & Rheumatology
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- (2015) Ali Jabbari et al. EBioMedicine
- Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol
- (2015) Eric R. Goedken et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia
- (2014) Lisa Pieri et al. AMERICAN JOURNAL OF HEMATOLOGY
- Ibrutinib for the Treatment of Mantle Cell Lymphoma
- (2014) A. F. Herrera et al. CLINICAL CANCER RESEARCH
- A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
- (2014) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- IL-9 and its receptor are predominantly involved in the pathogenesis of UC
- (2014) Nancy Nalleweg et al. GUT
- The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers
- (2014) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Inhibition of TYK2 and JAK1 Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis by Inhibiting IL-22 and the IL-23/IL-17 Axis
- (2014) Melissa G. Works et al. JOURNAL OF IMMUNOLOGY
- Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634
- (2014) Christel J. Menet et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
- (2014) J. Wollenhaupt et al. JOURNAL OF RHEUMATOLOGY
- Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy
- (2014) A. J. Gonzales et al. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS
- TH9 cells that express the transcription factor PU.1 drive T cell–mediated colitis via IL-9 receptor signaling in intestinal epithelial cells
- (2014) Katharina Gerlach et al. NATURE IMMUNOLOGY
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- (2014) Luzhou Xing et al. NATURE MEDICINE
- IL-6 biology: implications for clinical targeting in rheumatic disease
- (2014) Leonard H. Calabrese et al. Nature Reviews Rheumatology
- JAK–cytokine receptor recognition, unboxed
- (2014) Randall McNally et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Tofacitinib versus Methotrexate in Rheumatoid Arthritis
- (2014) Eun Bong Lee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib
- (2014) Thorsten Hornung et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
- (2014) Hector G. Ortega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Advances in kinase targeting: current clinical use and clinical trials
- (2014) Mathias Rask-Andersen et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials
- (2014) John D Isaacs et al. ARTHRITIS RESEARCH & THERAPY
- Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials: A Systematic Review and Meta-Analysis
- (2014) Alejandro Souto et al. Arthritis & Rheumatology
- Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
- (2013) Joel Kremer et al. ANNALS OF INTERNAL MEDICINE
- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
- (2013) Ying He et al. BMC MUSCULOSKELETAL DISORDERS
- Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
- (2013) L. Van Rompaey et al. JOURNAL OF IMMUNOLOGY
- Reversal of CD8 T-Cell–Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib
- (2013) Naoko Okiyama et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue
- (2013) J M Leung et al. Mucosal Immunology
- Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
- (2013) Rowan Wathes et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAKs and STATs in Immunity, Immunodeficiency, and Cancer
- (2013) John J. O'Shea et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities
- (2013) Jürgen Scheller et al. SEMINARS IN IMMUNOLOGY
- A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis
- (2013) Sallie B. Cosgrove et al. VETERINARY DERMATOLOGY
- Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year
- (2012) F. Vincenti et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
- (2012) Wolfgang Hueber et al. GUT
- SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis
- (2012) B. Madan et al. JOURNAL OF IMMUNOLOGY
- Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis
- (2012) Anthony D. William et al. JOURNAL OF MEDICINAL CHEMISTRY
- Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
- (2012) Naresh Punwani et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: Implication for atopic dermatitis
- (2012) Lei Bao et al. MOLECULAR IMMUNOLOGY
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye Disease
- (2012) Shiao Hui (Melissa) Liew et al. OPHTHALMOLOGY
- Origin and Function of Circulating Plasmablasts during Acute Viral Infections
- (2012) Katja Fink Frontiers in Immunology
- Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
- (2011) J. M. Kremer et al. ANNALS OF THE RHEUMATIC DISEASES
- Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling
- (2011) D. A. Hume et al. BLOOD
- Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors
- (2011) Claude Haan et al. CHEMISTRY & BIOLOGY
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
- (2011) Kamran Ghoreschi et al. JOURNAL OF IMMUNOLOGY
- FLT3 as a therapeutic target in AML: still challenging after all these years
- (2010) T. Kindler et al. BLOOD
- Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis
- (2010) A.-M. TOBIN et al. JOURNAL OF RHEUMATOLOGY
- An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis
- (2010) Michael E. Weinblatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis
- (2010) Chi Chiu Mok et al. ARTHRITIS CARE & RESEARCH
- Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the nurses' health study
- (2009) A. Elisabeth Hak et al. ARTHRITIS AND RHEUMATISM
- Revisiting Crohn's disease as a primary immunodeficiency of macrophages: Figure 1.
- (2009) Jean-Laurent Casanova et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
- Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
- (2008) Marc E. Rothenberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis
- (2008) Anthony J Milici et al. ARTHRITIS RESEARCH & THERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search